Angiogenesis is required for solid tumor growth and facilitates tumor progression and metastasis. The inhibition effects of O-（chloroacetyl-carbamoyl） fumagillol （TNP-470）, an angiogenesis inhibitor, and gemcitabi...Angiogenesis is required for solid tumor growth and facilitates tumor progression and metastasis. The inhibition effects of O-（chloroacetyl-carbamoyl） fumagillol （TNP-470）, an angiogenesis inhibitor, and gemcitabine, a chemotherapeutic agent, on expression of growth factors were investigated using human pulmonary adenocarcinoma cell line, A549. The A549 cells were divided into four groups： control group, 10^-6 mg/ml gemcitabine treated group, 10^-4 mg/ml TNP-470 treated group and gemcitabine＋TNP-470 treated group. The mRNA and protein expression of vascular endothelial growth factor （VEGF） and its receptors, FMS-like tyrosine kinase-l （FLT-1） and kinase insert domain-containing receptor （KDR）, in different groups were measured. The growth of A549 cell cultured with gemcitabine or TNP-470 was inhibited in an almost dose-dependent manner. Although gemcitabine （10^-6 mg/ml） alone and TNP-470 （10^-4 mg/ml） alone had no effect on the mRNA and protein expression of VEGF and its receptors （FLT-1, KDR） in A549 cells compared to the control （P〉0.05）, 10^-6 mg/ml gemcitabine in combination with 10^-4 mg/ml TNP-470 had significant effect （P〈0.01）. Moreover, combination of the two drugs significantly inhibited the mRNA expression of VEGF, FLT-1 and KDR compared to either drug alone （P〈0.05）. This study suggests that combined treatment with TNP-470 plus gemcitabine may augment the antiangiogenic and antineoplastic effects in lung cancer cells in vitro.展开更多
文摘Angiogenesis is required for solid tumor growth and facilitates tumor progression and metastasis. The inhibition effects of O-（chloroacetyl-carbamoyl） fumagillol （TNP-470）, an angiogenesis inhibitor, and gemcitabine, a chemotherapeutic agent, on expression of growth factors were investigated using human pulmonary adenocarcinoma cell line, A549. The A549 cells were divided into four groups： control group, 10^-6 mg/ml gemcitabine treated group, 10^-4 mg/ml TNP-470 treated group and gemcitabine＋TNP-470 treated group. The mRNA and protein expression of vascular endothelial growth factor （VEGF） and its receptors, FMS-like tyrosine kinase-l （FLT-1） and kinase insert domain-containing receptor （KDR）, in different groups were measured. The growth of A549 cell cultured with gemcitabine or TNP-470 was inhibited in an almost dose-dependent manner. Although gemcitabine （10^-6 mg/ml） alone and TNP-470 （10^-4 mg/ml） alone had no effect on the mRNA and protein expression of VEGF and its receptors （FLT-1, KDR） in A549 cells compared to the control （P〉0.05）, 10^-6 mg/ml gemcitabine in combination with 10^-4 mg/ml TNP-470 had significant effect （P〈0.01）. Moreover, combination of the two drugs significantly inhibited the mRNA expression of VEGF, FLT-1 and KDR compared to either drug alone （P〈0.05）. This study suggests that combined treatment with TNP-470 plus gemcitabine may augment the antiangiogenic and antineoplastic effects in lung cancer cells in vitro.
